O ROURKE & COMPANY Inc Sells 35 Shares of Amgen Inc. (NASDAQ:AMGN)

O ROURKE & COMPANY Inc cut its holdings in Amgen Inc. (NASDAQ:AMGNFree Report) by 2.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,227 shares of the medical research company’s stock after selling 35 shares during the quarter. O ROURKE & COMPANY Inc’s holdings in Amgen were worth $395,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in AMGN. Strategic Financial Concepts LLC bought a new stake in Amgen during the 2nd quarter worth approximately $26,000. Hershey Financial Advisers LLC bought a new stake in shares of Amgen during the 2nd quarter valued at $30,000. nVerses Capital LLC purchased a new position in shares of Amgen during the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC bought a new position in Amgen in the 2nd quarter worth $33,000. Finally, Matrix Trust Co bought a new position in Amgen in the 3rd quarter worth $36,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Bank of America boosted their price objective on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Robert W. Baird reiterated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research report on Wednesday, September 25th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $320.00 to $335.00 in a research report on Wednesday, August 7th. Finally, Truist Financial downgraded shares of Amgen from a “buy” rating to a “hold” rating and lifted their price target for the company from $320.00 to $333.00 in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

View Our Latest Analysis on Amgen

Amgen Price Performance

NASDAQ:AMGN traded up $6.26 during trading hours on Thursday, hitting $321.80. 770,824 shares of the stock were exchanged, compared to its average volume of 2,411,686. The firm’s fifty day moving average price is $324.75 and its 200 day moving average price is $314.78. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The company has a market cap of $172.62 billion, a P/E ratio of 45.08, a P/E/G ratio of 2.86 and a beta of 0.61. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the business earned $4.96 earnings per share. As a group, equities research analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.